Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression

Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression

Objective To investigate the rate of decline in forced vital capacity (FVC), and the effect of nintedanib on the rate of decline in FVC, in subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD) who had risk factors for rapid decline in FVC.Methods The SENSCIS trial enrolled...

Full description

Bibliographic Details
Main Authors: Toby M Maher, Michael Kreuter, Vanessa Smith, Yannick Allanore, Elizabeth R Volkmann, Dinesh Khanna, Christopher P Denton, Anna-Maria Hoffmann-Vold, Shervin Assassi, Masataka Kuwana, Margarida Alves, Christian Stock, Steven Sambevski
Format: Article
Language:English
Published: BMJ Publishing Group 2023-02-01
Series:RMD Open
Online Access:https://rmdopen.bmj.com/content/9/1/e002859.full

Internet

https://rmdopen.bmj.com/content/9/1/e002859.full

Similar Items